Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma March 26, 2024
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer March 26, 2024
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas March 26, 2024
Clasp Therapeutics Launches with $150 Million to Pioneer Precision IO Using Next-Gen T Cell Engagers with Unparalleled Specificity March 26, 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline March 18, 2024
IDEAYA to Evaluate IDE161 in Combination with KEYTRUDA in Patients with Endometrial Cancer March 18, 2024
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy March 18, 2024
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology March 18, 2024
Biotheus Expanded Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific ADCs March 18, 2024
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies March 12, 2024
AvantGen Receives Milestone Payment for First Patient Dosed in Ph 1 Study with Kite’s CAR-T Therapy March 12, 2024
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins March 12, 2024
Transgene, NEC, and BostonGene Expand Collaboration for Ph 1/2 Trial of Neoantigen Cancer Vaccine TG4050 March 12, 2024
Taiho Pharma Enters Exclusive License Agreement with Haihe Biopharma for Gumarontinib (SCC244), an Agent for NSCLC March 12, 2024
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers March 12, 2024
Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee March 4, 2024
Kite Receives U.S. FDA Approval Of Manufacturing Process Change to Reduce Median Turnaround Time For Yescarta March 4, 2024
Immunocore and BMS to evaluate IMC-F106C (PRAME HLA-A02) + Opdivo in registrational Ph 3 1L melanoma trial February 26, 2024
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology February 26, 2024
Immune-Onc Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate IO-108 in Ph 1b/2 Study for 1L Treatment of HCC February 26, 2024
